Vertex Pharmaceuticals Inc
VRTX509.500USD
+6.000+1.19%
收盤 04/30, 16:00（美東）報價延遲15分鐘
130.91B總市值
虧損本益比TTM
關於 Vertex Pharmaceuticals Inc 公司
Vertex Pharmaceuticals Incorporated 是一家全球性生物技術公司。該公司專注於投資科學創新，爲患有嚴重疾病的人創造變革性藥物，重點關注專業市場。該公司擁有四種獲批的治療囊性纖維化 (CF) 潛在病因的藥物，以及一種獲批的治療嚴重鐮狀細胞病 (SCD) 和輸血依賴性β地中海貧血 (TDT) 的療法。其產品線包括 CF、SCD、TDT、急性和神經性疼痛、APOL1 介導的腎臟疾病、1 型糖尿病、1 型肌強直性營養不良和 α-1 抗胰蛋白酶缺乏症的臨牀階段項目。其上市藥物包括 TRIKAFTA/KAFTRIO、SYMDEKO/SYMKEVI（tezacaftor/ivacaftor 和 ivacaftor）、ORKAMBI（lumacaftor/ivacaftor）和 KALYDECO（ivacaftor）。該公司正在開發非自體（同種異體）完全分化、幹細胞衍生的胰島細胞療法，旨在取代 1 型糖尿病患者體內被破壞的產生胰島素的胰島細胞。
公司簡介
公司代碼VRTX
公司名稱Vertex Pharmaceuticals Inc
上市日期Jul 24, 1991
成立日期1989
CEODr. Reshma Kewalramani
員工數量6100
證券類型Ordinary Share
年結日Jul 24
公司地址50 Northern Avenue
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02210
電話16173416393
網址https://www.vrtx.com/
公司代碼VRTX
上市日期Jul 24, 1991
成立日期1989
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Ms. Diana L. Mckenzie
Ms. Diana L. Mckenzie
Independent Director
Independent Director
8.63K
+485.29%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
--
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.43K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
地區USD
名稱
營收
佔比
United States
6.68B
60.66%
Europe
3.45B
31.34%
Other
881.30M
8.00%
業務
地區
業務USD
名稱
營收
佔比
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Capital World Investors
11.02%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
持股股東
股東統計
佔比
Capital World Investors
11.02%
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
股東類型
股東統計
佔比
Investment Advisor
48.67%
Investment Advisor/Hedge Fund
37.50%
Pension Fund
2.67%
Research Firm
2.17%
Bank and Trust
1.87%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.43%
Individual Investor
0.13%
Insurance Company
0.10%
Other
4.04%
機構持股
更新時間: 1月19日 週日
更新時間: 1月19日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
2878
247.84M
96.41%
-3.72M
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
2022Q4
2454
248.59M
96.73%
-7.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Capital World Investors
28.33M
11.02%
+1.51M
+5.65%
Dec 31, 2024
The Vanguard Group, Inc.
23.15M
9%
+102.48K
+0.44%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.33M
5.57%
-90.57K
-0.63%
Dec 31, 2024
State Street Global Advisors (US)
11.98M
4.66%
+163.16K
+1.38%
Dec 31, 2024
Capital Research Global Investors
10.43M
4.06%
+1.43M
+15.85%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.11M
3.54%
-1.25M
-12.07%
Dec 31, 2024
Wellington Management Company, LLP
5.92M
2.3%
+1.12M
+23.28%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.65M
2.2%
-287.65K
-4.85%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
5.33M
2.07%
+71.48K
+1.36%
Feb 28, 2025
JP Morgan Asset Management
4.62M
1.8%
-403.93K
-8.04%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
VanEck Biotech ETF
10.56%
Tema Neuroscience and Mental Health ETF
9.89%
Invesco Nasdaq Biotechnology ETF
8.48%
ProShares Ultra Nasdaq Biotechnology
8.08%
iShares Biotechnology ETF
7.22%
Indexperts Gorilla Aggressive Growth ETF
6.23%
Natixis Loomis Sayles Focused Growth ETF
4.96%
Franklin Genomic Advancements ETF
4.66%
Amplify AI Powered Equity ETF
4.21%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
查看更多
VanEck Biotech ETF
佔比10.56%
Tema Neuroscience and Mental Health ETF
佔比9.89%
Invesco Nasdaq Biotechnology ETF
佔比8.48%
ProShares Ultra Nasdaq Biotechnology
佔比8.08%
iShares Biotechnology ETF
佔比7.22%
Indexperts Gorilla Aggressive Growth ETF
佔比6.23%
Natixis Loomis Sayles Focused Growth ETF
佔比4.96%
Franklin Genomic Advancements ETF
佔比4.66%
Amplify AI Powered Equity ETF
佔比4.21%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.65%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據